Stock Comparison

ASTH vs JNJ

Astrana Health Inc vs Johnson & Johnson

The Verdict

ASTH takes this one.

Winner

ASTH

Astrana Health Inc

7.4

out of 10

Solid Pick

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$1.7B

Market Cap

$557.1B

77.7

P/E Ratio

26.5

0.7%

Profit Margin

21.8%

2.9%

Return on Equity

26.3%

1.3

Debt-to-Equity

0.6

Moderate

Overall Risk

Conservative

7.4

DVR Score

1.0

The Deep Dive

ASTH7.4/10

Astrana Health maintains its high-risk, high-reward profile, leveraging a rapidly expanding value-based care market with a clear strategic vision, particularly in Medicare Advantage and Medicaid. The company exhibits robust revenue growth (56% YoY in FY2025, 52.6% expected Q1 2026) and outperformance against its sector. Analyst consensus remains a 'Strong Buy' with significant upside. However, a m...

Full ASTH Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.